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Abstract. References are made to cytotoxic and/or antitumor compounds that have been isolated -
ansamitocin P-3 from Claopodium crispifolium (Hook.) Ren. & Card. and Anomodon attenuatus
Hueb., or an associated actinomycete, and ohioensins and pallidisetums from Polytrichum spp.
Several hundred collections, which have been obtained from temperate regions of North America
during 1990 and 1991, are currently being screened in new bioassays; active sesquiterpene lactones
have been recently isolated from species of Porella. The methodologies of collecting and screening
bryophyte samples are discussed with consideration to costs based on expected number of samples that
might be collected in a day, the diversity in the collections as related to phytogeography and vegetation
types, and the bryophyte cover that is vanishing in many forest regions of the United States. The
difficulties in obtaining large collections for isolation of active agents are also discussed by example-
recollection of Claopodium crispifolium.
Introduction
Plants, animals, fungi and microbes possess a
wide variety of chemical defensive and/or offen-
sive mechanisms as part of their survival strate-
gy; thus, it is not too surprising to learn that
nearly half of all medical prescriptions contain
ingredients derived from natural sources of which
20-25% are of plant origin (Marderosian &
Liberti 1988; Simpson & Conncer-Ogorzaly
1986). Taxol, isolated from the stembark of a
conifer, Taxus brevifolia, has recently been
recognized as a useful compound for treating
ovarian and mammarian cancers (Kingston 1991;
Rowinsky et al. 1990). However, it is estimated
that less than 3% of the plants or animals have
been thoroughly evaluated by pharmaceutical
industries, and there has only been a preliminary
screening of bryophytes for biological activities
(Spjut et al. 1986).194
Although a great potential exists for discovering
new drugs from natural product chemistry, the
methods in drug screening and evaluation are
perhaps still in their infancy. The screening of
natural products usually involves stepwise me-
thodical procedures of (1) detecting active che-
mical substances in crude extracts from a diver-
sity of species collections, (2) isolating chemical
agents from samples through fractionation gui-
ded by activity in bioassay systems, and (3)
chemical and pharmacological evaluation of
isolated active compounds employing correlati-
ve (accessory) bioassays that have predictability
in drug development; the term screening refers to
any one step or any combination of steps,
collectively. Discoveries of new drugs seem rare,
but pharmacological evaluation has often been
based on administration of active compounds
directly into the blood stream, with usually toxic
effects to many organs. On the other hand, if the
drug potential of active compounds can be eva-
luated for using more specific forms of drug
delivery, such as binding active agents with
carrier proteins or cells that function like antibo-
dies, then the number of new drug entities may
increase.
The discovery of novel active compounds from
natural product sources and their advancement
to clinical evaluation also depends on: (a) collec-
tion strategy, (b) the sensitivity of the bioassays
employed in preliminary screens (step 1 above),
(c) the predictiveness of clinical activity in acces-
sory bioassays, and (d) the flexibility to modify
bioassay systems, extraction methods and collec-
tion methodology as feedback is obtained from
identification and pharmacological evaluation
of active compounds.
It should be recognized that our screening me-
thodology in isolating compounds via bioassay-
activity-directed fractionation of extracted bryo-
phyte samples differs from that of many investi-
gators who have first isolated compounds before
testing them for biological activity (cf. Asakawa
1990). Additionally, a high incidence of biologi-
cal activity in screening crude extracts of bryo-
phyte species (e.g., McCleary & Walkington
1960; van Hoof et al. 1981) without reference to
the active compounds or to bioassays with a track
record of discovering novel active compounds,
may prove less significant if activity is largely
due to the presence of an ubiquitous compound.
Because relatively few active compounds have
been isolated by activity-directed fractionation of
bryophyte samples, we will review the progress
that has been made in the screening of bryophytes
and also discuss the factors that need to be
considered in collecting bryophytes for biological
screening programs. But first we will introduce
and define terminology generally employed in
the procurement and screening of plant samples
for biological activity.
Definitions
A natural product is an entire organism, or any
part of it, preserved, modified, extracted or
combined with other substances; this includes
whole microbes, whole animals, whole plants,
organs, plant parts, DNA, RNA or isolated che-
mical substances. Naturally occurring minerals
may also be included (Marderosian & Liberti
1988).
A biologically active substance is one that has
demonstrated significant experimental results
to: (a) increasing the life span of an organism or
its cultured cells; or (b) inhibiting cell growth or
preventing diseases, or (c) destroying peptides,
DNA or RNA, cells or organisms that are natu-
rally harmful to other organisms. These active
substances may be crude samples or crude ex-
tracts (mixtures of chemicals) or pure compounds;
the associated taxonomic names in a hierarchical
classification from which the active substances
are derived are also defined as active (e.g., the
active compound taxol from an active species,
Taxus brevifolia Nuttall; active genus, Taxus;
active family, Taxaceae).
Protocols for the NCI antitumor screening are
according to Geran et al. (1972) and Alley et al.
(1988).  The assays that have been employed for
screening bryophytes were briefly described in
Spjut et al. (1986).195
A collection refers to one or more samples of an
organism identified by a collector’s name(s) and
date of collection, classified by a species name
and documented by a voucher specimen. Bryo-
phytes are usually collected as whole samples
and not subdivided into parts, in contrast to
vascular plants (e.g., root, stembark, twig, leaf of
Taxus brevifolia).
The samples collected for the initial (prelimina-
ry) screening are referred to as general samples;
those obtained for chemical isolation and phar-
macological evaluation of the active agents are
termed recollections. The procurement of each
of these two types of samples require different
strategies in planning and execution, although
both kinds are often obtained during a single
field trip. The strategies for general samples and
recollections are later discussed separately in
this paper. Because activity in bryophytes may be
due to associated microorganisms, accessory
samples, or additional small samples, might be
obtained of an active species for reconfirmation
of activity.
Patents based on naturally occurring active
substances must not only include references to
the unique chemical structure(s), discovered
biological activities, isolation and purification
techniques, but also references to the source
materials -scientific name(s) of the organism(s)
and the scientific voucher specimen(s) as depo-
sited in an internationally recognized institution
(cf. Index Herbariorum, Holmgren et al. 1990).
Scientific names are subject to change as new
information is obtained, while the voucher spe-
cimen is a permanent reference point. For exam-
ple, taxol was first isolated from stembark sam-
ples of Taxus brevifolia, the only species of yew
generally thought to occur in the Pacific North-
west, which a USDA patent (Christen et al.
1991) was filed on obtaining taxol from tissue
cultures of this species; however, Spjut (in prep.)
recognizes the possibility of several varieties or
species of Taxus in the Pacific Northwest. Al-
though, the patent (Christen et al. 1991) stated
that any species of Taxus will produce the desired
results, this statement is unfounded.
Review of Antitumor Screening of Bryophytes
in 3PS (P-388), KB and ASK
The screening of bryophytes in the National
Cancer Institute’s (NCI) antitumor screening
program was reviewed by Spjut et. al. (1986).
Bryophytes were gathered in amounts of 250-
2000 g, extracted and tested against P-388 lym-
phocytic luekemia (in vivo), Cell Culture (9KB)
and astrocytoma (9ASK) cell lines. The test
results showed correlations with systematic bryo-
phyte groups, particularly in the Thuidiaceae,
Mniaceae and Neckeraceae. These results were
considered encouraging because the 9KB and P-
388 bioassays have lead to isolation of a diversity
of novel active compounds from samples of
vascular plant species (Hartwell 1976; Suffness
& Douros 1979) and taxol, first isolated during
the 1960’s from Taxus brevifolia, was discovered
by this screening methodology, which had also
included other bioassays (Hartwell 1976).
The first significant in vivo antitumor activity in
bryophytes was not discovered until 1979, based
on the collection of Claopodium crispifolium in
northwestern California during 1978 (Spjut et
al. 1986), in contrast to the discovery of taxol
from samples (of a conifer) first collected in
1962. Not all recollections of C. crispifolium
gave consistent test results, suggesting that asso-
ciated microorganism activity might be a factor
(Spjut et al. 1988). Indeed, ansamitocin P-3,
which has been isolated from a culture broth of
Nocardia sp. (Sakai et al. 1988), was isolated
from samples of C. crispifolium and Anomodon
attenuatus (Suwanborirux et al. 1990). But
maytansinoid compounds have also been isola-
ted from vascular plants, and it remains to be
shown whether the presence of these compounds
in terrestrial plants are produced directly by the
associated actinomycetes or are a chemical by-
product of a symbiotic relationship between the
actinomycete and the plant. Maytansinoid com-
pounds, which have been subjected to extensive
preclinical-pharmacological evaluation, are
highly toxic and, therefore, show little promise
in cancer chemotherapy.
Activity reported by Spjut et al. (1986) in species
of the Neckeraceae might also be due to maytan-196
sinoid compounds (Sakai et al. 1988) and, as a
result, one may wonder if antitumor activity in
bryophytes is largely due to chemical products
associated with actinomycetes. However, Cassa-
dy’s group has isolated novel polycyclic benzo-
naphthoxanthenones, ohioensins A, B, C, D and
E through fractionation guided by 9KB and 9PS
bioassay activity from samples of Polytrichum
ohioense Ren. & Card. (Cassady et al. 1990;
Zheng 1990; Zheng et al. 1989, 1992a). These
compounds, also active in the human tumor cell
lines (A-549 lung carcinoma, MCF-7 breast
adenocarcinoma and HT-29 colon adenocarci-
noma), are clearly moss-derived as the biogene-
tic pathway “apparently involves O-hydroxycin-
namate and hyroxylated bibenzyls as interme-
diates” (Huneck 1983; Suire & Asakawa 1981;
Zheng et al. 1989).
The possibility of a higher incidence of maytan-
sinoid activity in bryophytes in comparison to
other plant groups should not discourage further
screening of them. Rather, the screening metho-
dology simply should take this into considera-
tion. False-positive leads have previously been
encountered with new screening procedures or in
the screening of new groups of plants. For
example, tannins in angiosperms were showing
activity in approximately 10% of the aqueous
extract that were being tested in the WM and SA
tumor assays before the extraction procedure was
modified to precipitate out the tannins, but tannin-
sensitive tumor assays were also later dropped
from the screen (Hartwell 1976). Recently, lichen
polysaccharides in aqueous extracts have been
found to give false-positive leads in the NCI anti-
AIDS screen.
The cytotoxic compounds in species of Polytri-
chum, the ohioensins, were isolated from sam-
ples collected in lowland hardwood-pine forest
communities in Maryland based on an extract
(B-819218) from the original sample (Spjut 4357)
that showed only 9KB activity, whereas P-388
activity was reported from another extract (B-
856807) based on a sample collected in a conife-
rous (spruce-hemlock) bog forest of the White
Mountains in New Hampshire (Spjut 6449) (Spjut
et al. 1986). However, Spjut has reidentified the
voucher for the New Hampshire sample as Poly-
trichum pallidisetum Funck, a closely related
species that has been considered by some as
conspecific with P. ohioense.
Recollections of Polytrichum ohioense have been
obtained from many locations in Maryland and
from one location in Pennsylvania, and recollec-
tions of P. pallidisetum have been obtained from
New York, Vermont, New Hampshire and Ten-
nessee; ethanolic extracts prepared from all
samples were active. Although the activity was
originally determined from the 9KB and 3PS
assays, fractionation of the larger samples was
also guided by activity in the human tumor cell
lines A-549, HT-29, MCF-7, RPMI-7951 and
U251MG (Alley et al. 1988). In addition to the
isolation of ohioensins A through E from P.
ohioense, several other novel compounds, namely
1-O-methylohioensin B, 1-O
methyldihydroohioensin B, pallidisetin A and
pallidisetin B, were isolated from P. pallidisetum
(Zheng 1990; Zheng et al. 1992b). The
pallidisetins, which are active against RPMI-
7951 and U251MG cell lines, are novel cinnamoyl
bibenzyls that differ from the ohioensins
structurally. These two classes of compounds
may be derived via different biosynthetic pa-
thways from cinnamic acid and bibenzyls as the
common precursors. Thus, there appears to be a
biochemical activity distinction between the two
species.
Most of the active species reported by Spjut et al.
(1986) were collected during 1986-1989 in small
quantities (accessory samples) for reconfirma-
tion of activity, and those that reconfirmed were
recollected in large quantities for fractionation
and further screening. This work is being con-
ducted by one of our groups at Virginia Polytech-
nic Institute & State University. Some sixty
bryophytes were collected and screened against
the 9KB and 3PS assays. Twelve extracts showed
T/C >125 in the 3PS assay. Fractionation of these
extracts has not to date yielded any pure active
compounds; however, either activity was lost on
fractionation or recollections failed to confirm
the original results. It may be that activity is due
in part to associated organisms. Moreover, many
of the active species reported by Spjut et al.
(1986) were only marginally active. The relatively197
low percentage of reconfirmation in this particular
case should not discourage further screening of
bryophytes.
Screening of bryophytes in other bioassays
Several hundred new general samples have been
obtained since 1990 for antitumor screening in
new bioassays at Virginia Polytechnic Institute
& State University. These bioassays employ
genetically engineered yeast strains to detect
extracts that show DNA-damaging activity in
various ways. Activity is determined as an IC12
value, which is defined as the dose (in µg/ml)
necessary to produce a 12 mm zone of inhibition
in a repair-deficient yeast strain. For useful selec-
tive activity, the extract must be at least threefold
less active (i.e. have an IC12 at least three times
larger) in a repair-deficient yeast strain. An
extract is considered marginally active in its
initial screening if it has an IC12 value between
4000 and 8000, and moderately or highly active
if it has an IC12 value less than 4000; in each case
appropriate selectivity is required.
Based on these criteria, out of some 200 bryophy-
tes collected, a total of 22 (11%) had IC12 values
less than 4000 in at least one extract, while an
additional 27 had IC12 values in the 4000-8000
range. Four bryophytes (25) yielded extracts with
excellent IC12 values of less than 1000.
Regrettably, many of the active species collected
have failed to reconfirm activity on recollection.
One bryophyte, from which methanol extracts
were prepared, gave an IC12 value of 110 in the
initial small collection but IC12 value of greater
than 16,000 on recollection, even though recol-
lection was from the same locality as the original
sample. Another bryophyte with an IC12 value of
427 in one extract was also inactive on recollec-
tion. On the other hand, activity can sometimes
increase on recollections; one species with an
initial IC12 value of 4315, gave a much better IC12
value of 635 on recollection. In yet other cases,
activity is essentially constant between the initial
collection and the recollections. A sequiterpene
lactone has been isolated from a species of Porel-
la.
The failure of a significant number of bryophytes
to confirm activity on recollection may indicate
that the chemical constituents of these plants are
more sensitive to variation in the season, soil
type, etc. than what we have generally experien-
ced in the screening of vascular plants. Additio-
nally, the presence of associated microorganisms
that may affect the production of active agents in
a bryophyte may be subject to the same ecological
variables and, in those cases where activity was
highly significant, it may be worthwhile to culture
the microorganisms.
Systematic collection of general samples
The collection strategy employed by field biolo-
gists may be a systematic one in which species are
collected as encountered in selected geographic
areas, with consideration to phytogeographic
and taxonomic relationships as additional species
are screened (Spjut 1985), in contrast to selecting
species of plants according to their uses in folk
medicine, or on the basis of chemosystematic
data. The objective is to screen as much taxonomic
diversity as possible for the least cost. The factors
that need to be assessed in estimating procurement
costs are discussed first. Most bryophytes have
been collected in North America because
procurement and identification costs for these
samples are less expensive.
Second, the selection of a geographic area will be
exemplified by considering the phytogeography
and bryodiversity in tropical Africa. Considera-
tion is given not only to the phytogeographical
elements within political boundaries, but also to
previous collections that might have been obtai-
ned for screening and to the existence of the least-
disturbed vegetation types. Additionally,
bryophytes are mostly collectable in the upland
areas, whereas in the lowland areas they are
generally less abundant and often found in the
forest canopy.
Third, the NCI’s intent to develop cooperative
agreements with foreign institutions will be
mentioned. The long-term cooperation between
the host organization and the collectors is criti-198
cal. Although the discovery of a new drug might
be seen as a humanitarian benefit, especially in
regard to diseases like AIDS and cancer, there is
potential economic benefit to the host country by
the addition of a new agricultural commodity.
However, others feel that further compensation
in the form of royalities of 1-2% should be paid
to societies and/or governing institutions who
make their resources available to foreign drug
discovery programs, especially if drug discovery
is the result of contacts with local medical prac-
titioners.
Costs. Costs are a necessary consideration to
proposals and become part of the competitive
process for deciding awards; costs are then ac-
counted for in the activities of carrying out a
proposal. Scientists also have to report their
results if they want to continue their drug disco-
very efforts in screening bryophytes.
Cost estimates for general samples are based on
the expected number of species collections that
might be obtained in one day and the number of
days spent in the field before diminishing returns
on the daily yield becomes apparent. For exam-
ple, Spjut and Norris (Spjut et al. 1986) collected
on the average 6 bryophyte samples per day for a
period of several weeks in northern California
before it became obvious that further collecting
would not be productive in northern California.
The costs to collect bryophytes for pharmacolo-
gical screening are more difficult to estimate
than those for collecting samples of higher plants.
Bryofloras are less known for most areas and
field identification requires applying taxonomic
characters not easily visible with a hand lens.
Probably not more than 20% of the bryoflora in
an area is available in adequate quantity for
screening, but this estimate is being reduced by
deterioration of tropical and temperate vegeta-
tion due to clear-cutting, burning and atmosphe-
ric pollution. During 1986-1990, Spjut (1991)
noted the rapid disappearance of bryophyte cover
from rocks and soil near streams across North
America, and in the northeastern United States
many of the drier shaded rocks in forests that
were once recalled as being covered by bryophytes
and lichens, are now completely bare. As another
example, Thuidium erectum Duby (synonym T.
delicatulum (Hedw.) BSG), which was observed
in many forest communities of the eastern United
States prior to 1986, was rarely seen during field
work in 1990 and 1991; the same was also true
for lichen species of Peltigera. Some taxonomic
groups of bryophytes appear to be more tolerant
to pollutants (Spjut 1991; species of
Polytrichaceae and liverworts).
In many areas, bryophyte species are not easily
identified in the field, and laboratory identifica-
tion can be a costly activity. The bryotaxonomist
will not want to provide complete species names
until the taxonomic characters of the specimens
have been checked under a microscope and
compared with authenticated specimens in the
herbaria, sometimes requiring assistance from
other specialists. On the other hand, the ethno-
pharmacologist or ethnochemist, the one usually
designated as the project leader, is more concer-
ned about getting the samples into the screen.
Thus, there may have to be some compromise
between the level of taxonomic identification
and need for samples in the screen. This situation
is more applicable to bryophytes of tropical regions
where knowledge of the bryoflora is incomplete.
General collections that show activity should be
re-examined for identification before recollection.
Prior to 1985, general samples for preliminary
antitumor screening by NCI required 1 kg, and
up to 100 kg for isolation and identification of the
active constituents (Spjut et al. 1986, 1988).
Bryophyte samples are currently being screened
for antitumor activity by Virginia Polytechnic
Institute & State University utilizing samples
weighing less than 100 g. The lesser amount of
material has not changed the overall yield in
number of species collected because of apparent
diminishing bryophyte growth.
Cost effectiveness depends on the abilities of the
field personnel to distinguish species in the field
and to recognize which species are likely to be
available in sufficient quantity for screening.
This requires both training and practice. Fur-
thermore, it is also advantageous to employ a199
bryologist who has familiarity with the local
geography.
Diversity and Phytogeography. To exemplify
the phytogeographic approach, one might look at
the bryoflora of Africa. A good representation of
the African bryoflora might be obtained by first
collecting in Kenya from the following localities
as characterized by their vegetational/floristic
types: (1) Mount Londiani, a seasonally dry,
sclerophyll type forest, primarily found in the
montane regions of eastern Africa from Ethiopia
to Malawi; (2) Mount Kenya, typical of the Afro-
montane rain forest; (3) the Kikuyu Escarpment,
seasonally dry forest with many deciduous trees
and understory shrubs, somewhat spotty in
distribution, extending into southern Africa; and
(4) the Kakamega, an upland humid rain forest
with affinities to west African lowland rain forests.
Further collections in East Africa might be
obtained from the Usambara Mountains of
Tanzania where one may expect to find many
species not previously collected in Kenya because
of affinities to the bryoflora of Madagascar (Pócs
1975; Rodgers & Homewood 1982), which is in
contrast to the bryoflora of the southern highlands
of Tanzania that would yield fewer new species
because the bryoflora there has stronger affinities
to species that would have been collected on
Mount Kenya. Similar examples could be
described for Latin America, perhaps beginning
with Mexico taking into consideration its
phytogeography from data in Bartram (1949)
and Delgadillo (1971, 1979).
Prior to 1982, many taxa of vascular plants were
precluded from antitumor screening because of
known active compounds, e.g., cucurbitacins
(9KB activity) in species of Cucurbitaceae, car-
denolides (9KB activity) in Asclepias (Asclepia-
daceae), quassinoids (9KB and P-388 activity) in
species of Simaroubaceae (Spjut 1985). Grasses
were generally not collected because they rarely
showed activity. The screening of bryophytes has
never progressed to the point of precluding taxa
from collection, although one might want to
limit the number of species of Sphagnum in the
screen because of the numerous species in a
genus that has a cosmopolitan distribution; Spjut
et al. (1986) listed samples from ten or more
species that were screened but none were active.
In screening programs, there is often emphasis
on numerical quotas without regard to the taxo-
nomic diversity being represented in the sam-
ples. Spjut (1985) proposed an identification
manual that would make it possible for collectors
to readily identify many common tropical vascu-
lar plant species. The same author has also
considered developing a field key to common
bryophytes of North America; however, he is
discouraged by the rapid decline in bryophyte
cover in many regions; thus, such a key might
only have temporary value.
Cooperative agreements between collectors
and host countries. NCI, in developing agree-
ments with foreign government institutions,
expresses their intent to have a percentage of the
monetary profits from sales of new drugs be
returned to the country that was the originating
source of the natural product. NCI also will allow
foreign institution the first opportunity to deve-
lop the cultivation of the source for the drug.
World Botanical Associates proposes to follow
the NCI guidelines with modification to have the
monetary returns be divided among those insti-
tutions who collaborate based on the geographi-
cal distribution of a species since species are not
strictly confined to political boundaries.
Recollections
In biological screening of bryophytes, reconfir-
mation of bioassay activity should take into
consideration various associated microorganisms
(Spjut et al. 1988). Indeed, a bryophyte sample
might be viewed as a whole community of orga-
nisms dominated by a particular species of moss,
liverwort or hornwort. Therefore, an extracted
sample from a bryophyte species that shows
activity should be evaluated using new (accesso-
ry) samples of the same species of a moss from
different locations before large-scale collections
are obtained for isolation of the active com-
pounds.200
Recollections are often obtained by a trial and
error process of learning the ideal conditions
under which a species grows. For vascular plants,
locality data on herbarium specimens and publi-
cations on vegetational composition of species
often provide good leads to specific locations
where a species occurs in abundance; however,
bryotaxonomists in conducting floristic field
projects rarely provide information on the abun-
dance or luxuriance of growth for their collec-
tions. As already indicated, bryophyte identifica-
tion is based on microscopic characters, and
bryotaxonomists who collect for floristic reasons
will focus more on differences in microhabitats
to be certain of obtaining a good representation
of the flora rather than spend time in the field
being concerned about the identification and
abundance of a species. On the other hand, one
who is trained to collect for biological screening
programs will have developed the ability to auto-
matically keep a mental record on abundance of
species, which is particularly helpful when esti-
mates for the cost of recollections are requested.
Nonetheless, locality data on labels of bryophyte
herbarium specimens may narrow the geogra-
phical range of a search by the apparent concen-
tration of collections within an area.
Bryologists, of course, are able to recognize
certain species in the field, often in part by
taxonomic characters that can be seen with a
hand lens, and by other characters that are often
not mentioned in the keys. For instance, species
of Polytrichum and related genera are often
recognized at a glance by the miniature conifer-
like habit, i.e., erect stiff wiry stems bearing
spirally arranged needlelike leaves. Depending
on the knowledge of the bryoflora, field identifi-
cation to species is often possible; in North
America, Polytrichum piliferum Hedw. may be
identified by its preference for open sunny silice-
ous rocks and by examination of the leaf for the
presence of a whitish-hyaline awn and incurved
leaf margins that cover the lamellae.
Recollection of Claopodium crispifolium. The
recollections of up to 50 kg of Claopodium
crispifolium (Spjut et al. 1988) were largely
obtained by a trial and error process in field
observations to narrow the search to the most
preferred habitat type for the species. Prior to
conducting field work, Spjut compiled data on
ecology and geographical distribution from vari-
ous sources that included communication with
Daniel Norris, labels on herbarium specimens at
US and from Lawton (1971). C. crispifolium
appeared to have been frequently collected on
logs or on bark at the base of big-leaf maple (Acer
macrophyllum Pursh) in the redwood forest and
mixed-evergreen forest regions of northern Cali-
fornia to Washington. Norris also indicated that
C. bolanderi Best might be mistaken for C.
crispifolium, but as he further indicated this
species usually occurs on rock at higher eleva-
tions [in California (Spjut 1971) and in Oregon,
but not in Washington]. While this preliminary
information was generally accurate, it was still
inadequate for identifying sites with unusually
large quantities of C. crispifolium that were
needed for screening. As a result of conducting
transect-surveys of the coast ranges in California
and Oregon, C. crispifolium was most frequently
observed within a narrow longitudinal zone,
which seems to correspond to the most inland
occurrence of fog. This led to focusing the search
within this zone with further refinement to eleva-
tion, in California generally near 250 m altitude,
and in Oregon from 150-225 m altitude. The best
growth of C. crispifolium was then observed in
riparian forests of old growth maple or mixed
Douglas fir and maple. In addition to occurring
on bark or logs, this species was collected as a
dominant moss on large rocks (Spjut et al. 1988).
Approximately 7 days were spent conducting a
survey of the northern Coast Ranges of Califor-
nia and Oregon before reasonable collection sites
for C. crispifolium were found. Once the preferred
ecological parameters were learned, good
quantities of C. crispifolium could be located
within a days time.
Subsequent recollections of other bryophyte
species have required less investment of time for
learning ecological parameters, but
environmental pollution is throwing a ringer
into the learning curve because bryophytes are
simply dying out in many places. Currently, up to
three days are allowed for recollection of a201
bryophyte species. Recollections that require more
time are considered too expensive, unless the
screening results are highly active or significant
progress has already been made on isolating the
active compounds.
Environomental impact on recollecting Clao-
podium crispifolium. Samples of C. crispifo-
lium were collected in habitats where this species
was unusally abundant, thus, the removal of this
moss from various rocks and trees is expected to
have little effect on the surivival of the species
and its general distribution; nonetheless, the
structure of the remaining bryophyte-fern com-
munity has been changed and one may be concer-
ned about the redevelopment of the community
on the surface of rocks or trees that were exposed
as a result of collecting C. crispifoliun. The
recollections sites of C. crispifolium in California
(Spjut et al. 1988) were revisited by Spjut four
years later and he found these to be mostly bare;
however, Norris (pers. comm.) has since revisited
these sites and indicated that species of Encalypta
have filled in the bare spots. It is generally
recognized that the composition of bryophyte
cover on a particular habitat will change,
especially in secondary growth forests, but there
is little published information on changes in
bryophyte composition in seral communities.
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